Calcium channel blocker can attenuate the effect of Aldosterone on the ENaC
Not Applicable
Recruiting
- Conditions
- CKD
- Registration Number
- JPRN-UMIN000014060
- Lead Sponsor
- Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences
- Brief Summary
Five patients were enrolled.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Not provided
Exclusion Criteria
1) preceding treatment with CCB 4-week before enrollment 2) contra indications for study medications 3) presence/possibility for pregnancy/lactation 4) HbA1c ≥9.0% 5) GOT >100, or GPT >85 6) endocrine hypertension 7) accelerated or malignant hypertension 8) serious conditions with congestive heart failure, coronary diseases, arrhythmia or systemic diseases 9) any reason for ineligibility suggested by the attending doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How do calcium channel blockers modulate aldosterone-induced ENaC activity in CKD patients?
What is the comparative efficacy of CCBs versus ACE inhibitors in managing ENaC-related hypertension in CKD patients?
What biomarkers predict ENaC inhibition efficacy in JPRN-UMIN000014060 CKD trial?
What are the adverse event profiles of CCBs in CKD patients with aldosterone overactivity?
How do CCBs compare to aldosterone antagonists in suppressing ENaC activity for CKD progression?